ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 644

Expansion Of CD4+CXCR3+ T Cells In Patients With Systemic Lupus Erythematosus (SLE) Correlates With Subclinical Atherosclerosis

Karim Sacre1, Brigitte Escoubet2, Nicolas Charles3, Antoine Dossier4, Marie-Paule Chauveheid5 and Thomas Papo1, 1Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 2Cardiology, University Paris-7, INSERM U872, APHP, Bichat Hospital, Paris, France, 3INSERM U699, Paris, France, 4Internal Medicine, University Paris-7, APHP, Bichat Hospital, Paris, France, 5Internal Medicine,, University Paris-7, APHP, Bichat Hospital, Paris, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus, T cells and atherosclerosis

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Mechanisms and Biomarkers

Session Type: Abstract Submissions (ACR)

  • Background/Purpose:

The mechanisms for accelerated atherosclerosis in SLE remain unclear. As atherosclerosis is itself immune-mediated, features of SLE-associated immunity might explain accelerated cardiovascular disease beside traditional cardiovascular risk factors.We studied the relationship between T cells expressing CXCR3, a chemokine receptors involved in transendothelial migration, and subclinical vascular disease as assessed by common carotid intima-media thickness, internal carotid wall thickness, pulse wave velocity and pulse pressure measurements in SLE patients.

  • Methods:

The expression of CXCR3 on PBMCs was measured by flow cytometry in 33 SLE subjects asymptomatic for cardiovascular diseases (CVD) and 18 controls. Patients with SLE were assessed for vascular disease with common carotid artery intima-media thickness (IMT), internal carotid artery wall thickness (ICWT), pulse wave velocity (PWV), and pulse pressure (PP) as well as for SLE disease history, corticoid exposure and classical risk factors for cardiovascular disease.

  • Results:

All SLE subjects had received long-term glucocorticoid and 24 (73%) were still under prednisone at a mean daily dose of 8.7 ± 2.6 mg/day. All were receiving hydroxychloroquine. Twenty-four had been treated with immunosuppressive or immunomodulatory drugs during follow-up. Four patients also had APS. Classical cardiovascular risks distribution did not differ between controls and SLE patients (Table 1).

SLE-subjects displayed a higher frequency of circulating CD4+ T cells (35.1±17.7 vs 23.6±8.4%; p<0.05), CD8+ T cells (72.4±19.5 vs 44.9±14.9%; p<0.005), NKT cells (56.9±19.1 vs 31.3±18.8%; p<0.001) and B cells   (24.5±16.1 vs 12.4±5.9%; p<0.05) that expressed the chemokine receptor CXCR3, as compared to controls.

The mean IMT was 0.54 (±0.12) mm in SLE subjects. The mean internal carotid artery wall thickness (ICWT), pulse wave velocity (PWV), and pulse pressure (PP) was 1.34 (±0.74) mm, 7.1 (±1.65) m/s and 54.7 (± 13.3) mmHg, respectively.

In SLE subjects, infraclinical vascular disease -assessed with IMT (r2=0.15, p=0.02), ICWT (r2=0.12, p=0.04), PWV (r2=0.12, p=0.04), and PP (r2=0.23, p=0.004)- correlated with expression of CD4+CXCR3+ on T cells. CD4+CXCR3+ T cells were shown to be antigen-primed CD45RA–CD27+/- and to produce high levels of TNF-α upon polyclonal TCR activation..

No significant association was found between peripheral expansion of CD4+CXCR3+ T cells and traditional (Framingham score, LDL-cholesterol), non-traditional (HbA1c, homocystein, 25(OH)-D3 vitamin; creatinine blood levels) cardiovascular risk factors or SLE-related risk factors (duration of disease, glucocorticoid therapy, SLEDAI score, renal function).

  • Conclusion:

Our study suggests that CD4+CXCR3+ T cells are instrumental in SLE-associated atherosclerosis.

 

 

 

 

 

 


Disclosure:

K. Sacre,
None;

B. Escoubet,
None;

N. Charles,
None;

A. Dossier,
None;

M. P. Chauveheid,
None;

T. Papo,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-cd4cxcr3-t-cells-in-patients-with-systemic-lupus-erythematosus-sle-correlates-with-subclinical-atherosclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology